Antihypertensive medication changes and blood pressure goal achievement in a managed care population

Journal of Human Hypertension

Volumn 24, Issue 10, 2010, Pages 659-668

  Engel Nitz, N M ^a   Darkow, T ^a   Lau, H ^b  

^a Health Economics and Outcomes Research   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

antihypertensive; blood pressure; claims

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAL RECORD REVIEW; RETROSPECTIVE STUDY;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DRUG PRESCRIPTIONS; DRUG SUBSTITUTION; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; INSURANCE, PHARMACEUTICAL SERVICES; LOGISTIC MODELS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77956877357     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.2     Document Type: Article

References (20)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
2. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005; 45: 907-913.
3. Chobanian AV, Bakris GL, Black HR et al. and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Hypertension 2003; 42: 1206-1252.
4. Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension Awareness, Treatment, and Control-Continued Disparities in Adults: United States, 2005-2006. NCHS Data Brief No 3. National Center for Health Statistics: Hyattsville, MD, 2008.
5. Andrade SE, Gurwitz JH, Field TS et al. Hypertension management: the care gap between clinical guidelines and clinical practice. Am J Manag Care 2004; 10: 481-486.
6. Andros V, Egger A, Dua U. Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes. J Manag Care Pharm 2006; 12: 303-309.
7. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12: 239-245.
8. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40: 794-811.
9. Phillips LS, Branch WT, Cook CB et al. Clinical inertia. Ann Intern Med 2001; 135: 825-834.
10. Moser M, Franklin SS. Hypertension management: results of a new national survey for the hypertension education foundation: Harris interactive. J Clin Hypertens (Greenwich) 2007; 9: 316-323.
11. Ferrari P, the National Coordinators for the Reasons for not Intensifying Antihypertensive Treatment (RIAT) trial12. Reasons for therapeutic inertia when managing hypertension in clinical practice in non-Western countries. J Hum Hypertens 2009; 23: 151-159.
12. Kerr EA. The role of clinical uncertainty in treatment decisions for diabetic patients with uncontrolled blood pressure. Ann Intern Med 2008; 148: 717-727.
13. Rosen MI, Rigsby MO, Salahi JT, Ryan CE, Cramer JA. Electronic monitoring and counseling to improve medication adherence. Behav Res Therapy 2004; 42: 409-422.
14. Ho PM, Magid DJ, Shetterly SM et al. Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med 2008; 168: 271-276.
15. Heisler M, Hogan MM, Hofer TP, Schmittdiel JA, Pladevall M, Kerr EA. When more is not better: treatment intensification among hypertensive patients with poor medication adherence. Circulation 2008; 117: 2884-2892.
16. Rose AJ. Intensifying therapy for hypertension despite suboptimal adherence. Hypertension 2009; 54: 524-529.
17. Darkow T, Henk HJ, Thomas SK et al. Treatment interruptions and non-adherence with imatinib and associated health care costs: a retrospective analysis among managed care patients with chronic myelogenous leukemia. Pharmacoeconomics 2007; 25: 481-496.
18. Schneeweiss R, Rosenblatt RA, Cherkin DC, Kirkwood CR, Hart G. Diagnosis clusters: a new tool for analyzing the content of ambulatory medical care. Med Care 1983; 21: 105-122.
19. Ferrari P, Hess L, Pechere-Bertschi A, Muggli F, Burnier M. Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study. J Hypertens 2004; 22: 1221-1229.
20. O'Connor PJ. Overcome clinical inertia to control systolic blood pressure. Arch Intern Med 2003; 163: 2677-2678.